Results 21 to 30 of about 8,840 (216)

Inebilizumab in AQP4-Seropositive NMOSD: One-Year Follow-Up From a Multicenter, Real-World Study. [PDF]

Ann Clin Transl Neurol
ABSTRACT Objective Real‐world evidence on inebilizumab among neuromyelitis optica spectrum disorder (NMOSD) patients is lacking. This study assessed inebilizumab among Chinese patients with aquaporin 4 autoantibody (AQP4‐IgG)‐seropositive NMOSD in a real‐world setting.
Gui M, Zhan J, Li W, Jin T, He D, Tian D, Li Z, Lin J, Li Y, Zhou H, Bu B.   +10 more
europepmc   +2 more sources

Evaluation of Dried Plasma Spot-Based Quantification of Glial Fibrillary Acidic Protein as a Disease-Associated Biomarker in Neuromyelitis Optica Spectrum Disorder. [PDF]

Ann Clin Transl Neurol
ABSTRACT Objective To evaluate the diagnostic accuracy of glial fibrillary acidic protein (GFAP) measured in dried plasma spots versus conventional plasma‐ and serum‐GFAP testing for assessment of disease severity in aquaporin‐4 immunoglobulin G–positive neuromyelitis optica spectrum disorder (AQP4‐IgG+ NMOSD).
Wohlrab F, Alvarez E, Hamdi R, Zhang B, Ji H, Jhaveri N, Schindler P, Sanchez P, Sperber PS, Schmitz-Hübsch T, Oertel FC, Vorasoot N, Kissani N, Böhringer F, Kuhle J, Pröbstel AK, Ma XJ, Körtvelyessy P, Waters P, Paul F.   +19 more
europepmc   +2 more sources

NMOSD and MS prevalence in the Indigenous populations of Australia and New Zealand

, 2021
BACKGROUND: We studied the prevalence of neuromyelitis optica spectrum disorder (NMOSD) and multiple sclerosis (MS) in Indigenous populations of Australia and New Zealand with the aim of assessing potential differences.
Fabis-Pedrini, Marzena, Mason, Deborah F, Bukhari, Wajih, Khalilidehkordi, Elham, Taylor, Bruce V, Australian and New Zealand NMO Collaboration, Barnett, Michael H, Subramanian, Sankar, Broadley, Simon A, Waters, Patrick, Kermode, Allan G   +10 more
core   +3 more sources

Apheresis therapies for NMOSD attacks

, 2018
\(\bf Objective\) To analyze whether 1 of the 2 apheresis techniques, therapeutic plasma exchange (PE) or immunoadsorption (IA), is superior in treating neuromyelitis optica spectrum disorder (NMOSD) attacks and to identify predictive factors for complete remission (CR).
Kleiter, Ingo Wolfram (Prof. Dr. med.), Trebst, Corinna (Prof. Dr. med.), Hellwig, Kerstin (Prof Dr. med.), Linker, Ralf A. (Prof. Dr. med.), Schwab, Matthias, Gahlen, Anna Maria (Dr. med.), Borisow, Nadja (Dr. med.), Fischer, Katrin, Pache, Florence (Dr. med.), Ruprecht, Klemens (Prof. Dr. med.), Havla, Joachim (PD Dr. med.), Kümpfel, Tanja, Aktaş, Orhan (Univ.-Prof. Dr. med.), Hartung, Hans-Peter, Ringelstein, Marius (PD Dr. med.), Geis, Christian, Kleinschnitz, Christoph, Berthele, Achim (Prof. Dr. med.), Hemmer, Bernhard, Angstwurm, Klemens, Steilmann, Jan-Patrick, Schuster, Simon, Stangel, Martin, Lauda, Florian, Tumani, Hayrettin, Mayer, Christoph, Krumpholz, Markus, Zeltner, Lena, Ziermann, Ulf, Marziniak, Martin, Then Bergh, Florian, Hofstadt-van Oy, Ulrich, Neuhaus, Oliver, Zettl, Uwe K., Faiss, Jürgen, Wildemann, Brigitte (Prof. Dr. med.), Paul, Friedemann (Prof. Dr. med.), Jarius, Sven, Wernecke, Klaus-Dieter (Prof. Dr. rer. nat. habil.)   +38 more
openaire   +2 more sources

Opsoclonus‐Myoclonus‐Ataxia Revealing Underlying Neuromyelitis Optica Spectrum Disorder [PDF]

Mov Disord Clin Pract
Movement Disorders Clinical Practice, EarlyView.
Verde A, de Paiva Santos Rolim F, Catunda A, Filho J, Pitombeira M, Carvalho F, de Assis Pereira Matos P.   +6 more
europepmc   +2 more sources

Incidence and prevalence of NMOSD in Australia and New Zealand [PDF]

, 2017
OBJECTIVES: We have undertaken a clinic-based survey of neuromyelitis optica spectrum disorders (NMOSDs) in Australia and New Zealand to establish incidence and prevalence across the region and in populations of differing ancestry. BACKGROUND: NMOSD is a
KM Prain (14464830), K Boundy (9861470), WM Carroll (14464797), C Chen (7708955), S Blum (13420548), S Bhuta (13420545), K Dear (13435722), M Walsh (7993829), JA Pereira (14544800), AG Kermode (14464779), J Lechner-Scott (13311723), C Kneebone (13420590), SW Reddel (14544803), MP Marriott (14464818), S Vucic (13311915), J Stankovich (13420611), I Sutton (13420614), H Butzkueven (9887432), RA Silvestrini (14464836), J Spies (13435740), W Bukhari (13420521), JD Pollard (14464827), RJ Wilson (7926350), E Willoughby (13420635), S Jimenez-Sanchez (13513276), M Woodhall (13420533), C Das (13420566), DF Mason (14464773), D Gillis (13420572), APD Henderson (14464803), RC Dale (14464800), L Clarke (10130051), WJ Brownlee (14464791), Cameron Shaw (13094307), CS Bundell (14464794), C Lynch (11139258), T Killpatrick (13629475), M Brown (7628567), MJ Fabis-Pedrini (14544797), RC Wong (14464839), D Fulcher (13435725), S Hodgkinson (13311777), EM Yiu (14464842), M Boggild (13420551), BV Taylor (14461782), A Vincent (7756613), M Slee (13311747), A Coulthard (13359423), P Waters (13420641), M-W Lin (13629478), MH Barnett (14464776), JDE Parratt (14464824), PA McCombe (14464821), SA Broadley (14464782), CM O'Gorman (14544794), R Macdonell (10539110), BJ Brew (14464788), S Hawke (13420575), D Abernethy (13435716), S Heshmat (13420584), MP Pender (14461785), AJ Kornberg (14464809), R Heard (13420578), J King (7721714)   +63 more
core   +5 more sources

Epidemiology of Pediatric NMOSD in Germany and Austria [PDF]

Frontiers in Neurology, 2020
Background: Neuromyelitis optica spectrum disorders (NMOSD) are severe inflammatory demyelinating disorders of the central nervous system mainly characterized by recurrent episodes of uni- or bilateral optic neuritis (ON), transverse myelitis (TM) and brainstem syndromes (BS).
Christian Lechner, Markus Breu, Eva-Maria Wendel, Barbara Kornek, Kathrin Schanda, Matthias Baumann, Markus Reindl, Kevin Rostásy   +7 more
openaire   +3 more sources

Prevalence of NMOSD and MS in the Indigenous Populations of Australia and New Zealand

, 2020
Background: Neuromyelitisoptica spectrum disorders (NMOSD) and multiple sclerosis (MS) have differing population frequencies according to ethnic ancestry.
Fabis-Pedrini, M, Bukhari, W, Subramanian, S, Broadley, SA, Mason, F, Barnett, MH, Kermode, AG, Waters, P, Khalilidehkordi, E, Taylor, B   +9 more
core   +2 more sources

Higher longitudinal brain white matter atrophy rate in aquaporin-4 IgG-positive NMOSD compared with healthy controls

Scientific Reports, 2023
We aimed to compare longitudinal brain atrophy in patients with neuromyelitis optica spectrum disorder (NMOSD) with healthy controls (HCs). The atrophy rate in patients with anti-aquaporin-4 antibody-positive NMOSD (AQP4 + NMOSD) was compared with age ...
Hiroki Masuda, Masahiro Mori, Shigeki Hirano, Akiyuki Uzawa, Tomohiko Uchida, Mayumi Muto, Ryohei Ohtani, Reiji Aoki, Yoshiyuki Hirano, Japanese Alzheimer’s Disease Neuroimaging Initiative (J-ADNI), Satoshi Kuwabara   +10 more
doaj   +1 more source

Age of onset correlates with clinical characteristics and prognostic outcomes in neuromyelitis optica spectrum disorder

Frontiers in Immunology, 2022
ObjectiveNeuromyelitis optica spectrum disorder (NMOSD) is an inflammatory disease preferentially affects the optic nerve and the spinal cord. The first attack usually occurs in the third or fourth decade, though patients with disease onset in the ...
Yacen Hu, Yacen Hu, Qiying Sun, Qiying Sun, Fang Yi, Fang Yi, Lingyan Yao, Lingyan Yao, Yun Tian, Yun Tian, Haiyun Tang, Mengchuan Luo, Mengchuan Luo, Nina Xie, Nina Xie, Zhiqin Wang, Zhiqin Wang, Xinxin Liao, Xinxin Liao, Lin Zhou, Lin Zhou, Hongwei Xu, Hongwei Xu, Hongwei Xu, Yafang Zhou, Yafang Zhou   +25 more
doaj   +1 more source